0 3 Two two CD 4 12 distinct distinct JJ 13 21 pathways pathway NNS 22 24 of of IN 25 38 interleukin-5 interleukin-5 NN 39 48 synthesis synthesis NN 49 51 in in IN 52 69 allergen-specific allergen-specific JJ 70 75 human human JJ 76 82 T-cell t-cell NN 83 89 clones clone NNS 90 93 are be VBP 94 104 suppressed suppress VBN 105 107 by by IN 108 123 glucocorticoids glucocorticoid NNS 123 124 . . . 126 141 Glucocorticoids Glucocorticoid NNP 142 143 ( ( ( 143 145 GC GC NNP 145 146 ) ) ) 147 151 have have VBP 152 156 long long RB 157 161 been be VBN 162 166 used use VBN 167 169 as as IN 170 173 the the DT 174 178 most most RBS 179 188 effective effective JJ 189 195 agents agent NNS 196 199 for for IN 200 203 the the DT 204 213 treatment treatment NN 214 216 of of IN 217 225 allergic allergic JJ 226 234 diseases disease NNS 235 246 accompanied accompany VBN 247 249 by by IN 250 262 eosinophilia eosinophilia NN 263 267 such such JJ 268 270 as as IN 271 278 chronic chronic JJ 279 285 asthma asthma NN 286 289 and and CC 290 296 atopic atopic JJ 297 307 dermatitis dermatitis NN 307 308 . . . 309 312 The the DT 313 324 development development NN 325 327 of of IN 328 335 chronic chronic JJ 336 348 eosinophilic eosinophilic JJ 349 361 inflammation inflammation NN 362 364 is be VBZ 365 374 dependent dependent JJ 375 377 on on IN 378 391 interleukin-5 interleukin-5 NN 392 393 ( ( ( 393 397 IL-5 IL-5 NNP 397 398 ) ) ) 398 399 , , , 400 401 a a DT 402 411 selective selective JJ 412 433 eosinophil-activating eosinophil-activating JJ 434 440 factor factor NN 440 441 , , , 442 450 produced produce VBN 451 453 by by IN 454 460 helper helper NN 461 462 T t NN 463 468 cells cell NNS 468 469 . . . 470 472 To to TO 473 482 delineate delineate VB 483 486 the the DT 487 497 regulatory regulatory JJ 498 508 mechanisms mechanism NNS 509 511 of of IN 512 517 human human JJ 518 522 IL-5 il-5 NN 523 532 synthesis synthesis NN 532 533 , , , 534 536 we we PRP 537 548 established establish VBD 549 566 allergen-specific allergen-specific JJ 567 571 CD4+ cd4+ JJ 572 578 T-cell t-cell NN 579 585 clones clone NNS 586 590 from from IN 591 600 asthmatic asthmatic JJ 601 609 patients patient NNS 609 610 . . . 611 613 GC GC NNP 614 625 efficiently efficiently RB 626 636 suppressed suppress VBD 637 641 IL-5 il-5 NN 642 651 synthesis synthesis NN 652 654 of of IN 655 661 T-cell t-cell NN 662 668 clones clone NNS 669 678 activated activate VBN 679 682 via via IN 683 689 either either CC 690 696 T-cell t-cell NN 697 705 receptor receptor NN 706 707 ( ( ( 707 710 TCR TCR NNP 710 711 ) ) ) 712 714 or or CC 715 719 IL-2 il-2 NN 720 728 receptor receptor NN 729 730 ( ( ( 730 735 IL-2R IL-2R NNP 735 736 ) ) ) 736 737 . . . 738 747 Induction Induction NNP 748 750 of of IN 751 755 IL-5 IL-5 NNP 756 760 mRNA mRNA NNP 761 765 upon upon IN 766 769 TCR TCR NNP 770 773 and and CC 774 779 IL-2R IL-2R NNP 780 791 stimulation stimulation NN 792 795 was be VBD 796 803 totally totally RB 804 813 inhibited inhibit VBN 814 816 by by IN 817 830 dexamethasone dexamethasone NN 830 831 . . . 832 837 Human human JJ 838 842 IL-5 IL-5 NNP 843 871 promoter/enhancer-luciferase promoter/enhancer-luciferase NN 872 876 gene gene NN 877 886 construct construct NN 887 898 transfected transfecte VBN 899 901 to to TO 902 908 T-cell t-cell NN 909 915 clones clone NNS 916 919 was be VBD 920 931 transcribed transcribe VBN 932 934 on on IN 935 941 either either CC 942 945 TCR TCR NNP 946 948 or or CC 949 954 IL-2R IL-2R NNP 955 966 stimulation stimulation NN 967 970 and and CC 971 974 was be VBD 975 982 clearly clearly RB 983 996 downregulated downregulate VBN 997 999 by by IN 1000 1013 dexamethasone dexamethasone NN 1013 1014 , , , 1015 1025 indicating indicate VBG 1026 1030 that that IN 1031 1034 the the DT 1035 1048 approximately approximately RB 1049 1055 500-bp 500-bp JJ 1056 1061 human human JJ 1062 1066 IL-5 il-5 NN 1067 1071 gene gene NN 1072 1079 segment segment NN 1080 1087 located locate VBN 1088 1089 5 5 CD 1089 1090 ’ ' SYM 1091 1099 upstream upstream RB 1100 1102 of of IN 1103 1106 the the DT 1107 1113 coding cod VBG 1114 1120 region region NN 1121 1129 contains contain VBZ 1130 1150 activation-inducible activation-inducible JJ 1151 1159 enhancer enhancer NN 1160 1168 elements element NNS 1169 1180 responsible responsible JJ 1181 1184 for for IN 1185 1188 the the DT 1189 1199 regulation regulation NN 1200 1202 by by IN 1203 1205 GC GC NNP 1205 1206 . . . 1207 1222 Electrophoretic electrophoretic JJ 1223 1231 mobility mobility NN 1232 1237 shift shift NN 1238 1243 assay assay NN 1244 1252 analysis analysis NN 1253 1262 suggested suggest VBD 1263 1267 that that IN 1268 1272 AP-1 ap-1 NN 1273 1276 and and CC 1277 1286 NF-kappaB NF-kappaB NNP 1287 1290 are be VBP 1291 1296 among among IN 1297 1300 the the DT 1301 1309 possible possible JJ 1310 1317 targets target NNS 1318 1320 of of IN 1321 1323 GC GC NNP 1324 1331 actions action NNS 1332 1334 on on IN 1335 1349 TCR-stimulated tcr-stimulated JJ 1350 1351 T t NN 1352 1357 cells cell NNS 1357 1358 . . . 1359 1364 NF-AT NF-AT NNP 1365 1368 and and CC 1369 1378 NF-kappaB NF-kappaB NNP 1379 1383 were be VBD 1384 1387 not not RB 1388 1401 significantly significantly RB 1402 1409 induced induce VBN 1410 1412 by by IN 1413 1417 IL-2 il-2 NN 1418 1429 stimulation stimulation NN 1429 1430 . . . 1431 1434 Our our PRP$ 1435 1442 results result NNS 1443 1450 showing show VBG 1451 1455 that that IN 1456 1458 GC GC NNP 1459 1469 suppressed suppress VBD 1470 1474 IL-5 il-5 NN 1475 1485 production production NN 1486 1488 by by IN 1489 1494 human human JJ 1495 1499 CD4+ cd4+ JJ 1500 1501 T t NN 1502 1507 cells cell NNS 1508 1517 activated activate VBN 1518 1520 by by IN 1521 1524 two two CD 1525 1533 distinct distinct JJ 1534 1541 stimuli stimulus NNS 1541 1542 , , , 1543 1546 TCR TCR NNP 1547 1550 and and CC 1551 1556 IL-2R IL-2R NNP 1557 1568 stimulation stimulation NN 1568 1569 , , , 1570 1580 underscore underscore VBP 1581 1584 the the DT 1585 1593 efficacy efficacy NN 1594 1596 of of IN 1597 1599 GC GC NNP 1600 1602 in in IN 1603 1606 the the DT 1607 1616 treatment treatment NN 1617 1619 of of IN 1620 1628 allergic allergic JJ 1629 1637 diseases disease NNS 1638 1641 via via IN 1642 1653 suppression suppression NN 1654 1656 of of IN 1657 1663 T-cell T-cell NNP 1664 1668 IL-5 IL-5 NNP 1669 1678 synthesis synthesis NN 1678 1679 . . .